Myriad Genetics Completes Acquisition of Precise Tumor, : vi

SALT LAKE CITY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...

Related Keywords

Utah , United States , Matt Scalo , Glenn Farrell , Intermountain Health , Nasdaq , Exchange Commission , Genetics Inc , Intermountain Precision Genomics , Tumor Test , Precise Liquid Test , Precise Tumor Test , Solid Tumor , Precise Tumor , Precise Liquid , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Nasdaq Mygn , Myriad Genetics , Nc ,